{"id":1007370,"date":"2026-10-01T07:42:34","date_gmt":"2026-10-01T11:42:34","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/roswell-park-generate-biomedicines-launch-exclusive-clinical-trial-of-armored-car-t-therapy-for-ovarian-cancer\/"},"modified":"2026-10-01T07:42:34","modified_gmt":"2026-10-01T11:42:34","slug":"roswell-park-generate-biomedicines-launch-exclusive-clinical-trial-of-armored-car-t-therapy-for-ovarian-cancer","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/roswell-park-generate-biomedicines-launch-exclusive-clinical-trial-of-armored-car-t-therapy-for-ovarian-cancer\/","title":{"rendered":"Roswell Park, Generate Biomedicines Launch Exclusive Clinical Trial of \u2018Armored\u2019 CAR T Therapy for Ovarian Cancer"},"content":{"rendered":"
\n

\n Engineered with AI to optimize T-cell function in solid tumors, GB-5267 is the first next-generation cell therapy for ovarian cancer to enter clinical trials<\/em>\n <\/p>\n

First patient treated in new clinical trial underway at Roswell Park<\/p>\n

Treatment is designed to avoid pre-infusion chemotherapy and its side effects<\/p>\n

GB-5267 targets MUC16, a biomarker over-expressed in +80% of ovarian tumors<\/p>\n

BUFFALO, N.Y. and SOMERVILLE, Mass., Oct. 01, 2026 (GLOBE NEWSWIRE) — Roswell Park Comprehensive Cancer Center (\u201cRoswell Park\u201d) and Generate Biomedicines, Inc. (\u201cGenerate\u201d) today announced that the first patient has been dosed in a first-in-human clinical trial evaluating GB-5267<\/a>, an investigational, autologous IL-18 armored CAR T-cell therapy designed to overcome key barriers that have limited the success of cellular therapies in ovarian cancer and other solid tumors. GB-5267 targets the antigen MUC16, which is over-expressed by more than 80% of ovarian tumors and helps them grow, spread, and hide from the immune system. The trial is recruiting patients whose disease has returned after treatment or does not respond to platinum-based chemotherapy, the standard first-line treatment.<\/p>\n

Led by Principal Investigator Emese Zsiros, MD, PhD, FACOG<\/a>, Chair of Gynecologic Oncology at Roswell Park, the phase 1 clinical trial (NCT07489287<\/a>) will evaluate the safety and tolerability of GB-5267.<\/p>\n

Each patient\u2019s T cells, immune cells capable of killing cancer cells, will be collected, genetically engineered, and expanded in Roswell Park\u2019s GMP Engineering & Cell Manufacturing Facility<\/a> before being returned to the patient to target an attack against the tumor.<\/p>\n

While T-cell therapies have revolutionized the treatment of blood cancers, leading to long-term remission or even cure for many patients, solid tumors \u2014 cancers that grow in organs or tissue \u2014 have posed more of a challenge. That\u2019s because the tumor\u2019s microenvironment, a protective cocoon that surrounds it, prevents immune cells from entering the tumor or even being able to recognize it. But investigators believe they have found a way around that roadblock.<\/p>\n

\u201cWe\u2019re armoring the T cells with IL-18, a cytokine that will help protect them from the suppressive microenvironment of the solid tumor,\u201d explains Marco Davila, MD, PhD<\/a>, Senior Vice President and Associate Director for Translational Research at Roswell Park. Dr. Davila co-developed some of the first CAR T-cell therapies and has played a key role in refining them.<\/p>\n

\u201cBecause ovarian cancer spreads through the peritoneal cavity, the CAR T-cell therapy will be delivered in two ways: intravenously and into the peritoneal cavity,\u201d adds Dr. Zsiros. \u201cThis strategy is designed to concentrate the immune response where it is needed, without the toxicity of high-dose chemotherapy.\u201d<\/p>\n

GB-5267 was engineered by Generate with AI through the design and evaluation of CAR architectures at scale based on how T cells actually behave, rather than relying on binding affinity as a proxy for performance. GB-5267 was designed to optimize three interdependent functions required for CAR T-cell performance in solid tumors:<\/p>\n